.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A randomized controlled trial in India evaluated prophylactic tranexamic acid before cesarean delivery among women at high risk of postpartum hemorrhage. The study found reduced calculated blood loss with tranexamic acid compared with placebo, supporting its potential role in prevention alongside established obstetric hemorrhage protocols. For clinicians, the important distinction is between prophylaxis in selected high-risk patients and treatment of established PPH, where urgent therapeutic administration remains time-sensitive. Risk assessment should include placenta-related bleeding risk, anemia, previous PPH, multiple gestation and other clinical factors. Tranexamic acid does not replace uterotonics, blood-bank preparedness or mechanical and surgical measures when bleeding is severe. The trial is particularly relevant to practical protocol development because it demonstrates how a relatively simple pharmacologic intervention can be incorporated into cesarean pathways. Local guidelines and contraindications should always be considered when applying prophylactic strategies.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A randomized controlled trial in India evaluated prophylactic tranexamic acid before cesarean delivery among women at high risk of postpartum hemorrhage. The study found reduced calculated blood loss with tranexamic acid compared with placebo, supporting its potential role in prevention alongside established obstetric hemorrhage protocols. For clinicians, the important distinction is between prophylaxis in selected high-risk patients and treatment of established PPH, where urgent therapeutic administration remains time-sensitive. Risk assessment should include placenta-related bleeding risk, anemia, previous PPH, multiple gestation and other clinical factors. Tranexamic acid does not replace uterotonics, blood-bank preparedness or mechanical and surgical measures when bleeding is severe. The trial is particularly relevant to practical protocol development because it demonstrates how a relatively simple pharmacologic intervention can be incorporated into cesarean pathways. Local guidelines and contraindications should always be considered when applying prophylactic strategies.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
